Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03703063 | Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer | unknown | Phase 1 | 30 | Benaroya Research InstituteOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT03794440 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | unknown | Phase 2 / Phase 3 | 595 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 22, 2021 |
| clinicaltrials |
| NCT04665362 | IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | unknown | Phase 1 | 10 | Liang PengOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT04479527 | Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 34 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 14, 2021 | clinicaltrials |
| NCT04687163 | Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04183088 | Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 125 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04677088 | TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation | unknown | Phase 1 | 7 | Xiaoshun HeOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04640116 | TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites | unknown | N/A | 30 | Sun Yat-sen UniversityOTHER | 0 | Dec 19, 2020 | clinicaltrials |
| NCT04667351 | HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04653701 | Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC | unknown | — | 30 | Juan José Ciampi DopazoOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04652492 | Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 72 | Zhongda HospitalOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04619342 | Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT) | unknown | N/A | 98 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT03898921 | RFA vs. SBRT for Small HCC | unknown | Phase 3 | 270 | Sun Yat-sen UniversityOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT04636788 | Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer | unknown | N/A | 102 | Huazhong University of Science and TechnologyOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT03474341 | Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer(PRIDE) | unknown | — | 200 | UMC UtrechtOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT04627363 | HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Nov 13, 2020 | clinicaltrials |
| NCT04621370 | A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer(PRIME-RT) | unknown | Phase 2 | 48 | Liz-Anne LewsleyOTHER | 0 | Nov 9, 2020 | clinicaltrials |
| NCT04317248 | "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma | unknown | Phase 2 | 600 | Yuehua HuangOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT02046356 | Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation | unknown | — | 139 | Yunhua TanOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04181931 | Neo-TACE-HAIC for PVTT-HCC(NeoconceptC) | unknown | N/A | 320 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04424043 | Neo-TACE-HAIC for BCLC B Stage HCC(NeoconceptB) | unknown | N/A | 280 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 70 | Johannes Gutenberg University MainzOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04597970 | TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC(OXRI) | unknown | Phase 2 | 66 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT04076631 | Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma | unknown | — | 1,000 | Chen XiaopingOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT01703650 | Role of Perfusion CT in Pancreatic Cancer | unknown | — | 48 | Seoul National University HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03138213 | Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy | unknown | N/A | 656 | Tongji HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | unknown | N/A | 18 | Kang YUOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04454762 | A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function(CaboCHILD) | unknown | Phase 2 | 20 | Johannes Gutenberg University MainzOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04411589 | The Diagnostic Ability of White Light Endoscopy and Magnifying Endoscopy With Optical Enhancement System | unknown | N/A | 300 | Shandong UniversityOTHER | 1 | Sep 25, 2020 | clinicaltrials |
| NCT04550663 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | unknown | Phase 1 | 10 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT04560751 | TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) | unknown | — | 300 | Zhejiang Cancer HospitalOTHER | 0 | Sep 23, 2020 | clinicaltrials |
| NCT04552236 | Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment | unknown | — | 100 | Assiut UniversityOTHER | 0 | Sep 17, 2020 | clinicaltrials |
| NCT04538313 | A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs | unknown | Phase 1 / Phase 2 | 40 | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.NETWORK | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03754192 | Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma(PERCAHEC) | unknown | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT04523467 | Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma | unknown | N/A | 320 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT04523662 | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 27 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04057274 | Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth(AEROBIC) | unknown | N/A | 16 | Northumbria UniversityOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04520295 | ctDNA Screening in Advanced HER2 Positive Gastric Cancer | unknown | — | 100 | Ruijin HospitalOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04521491 | A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells | unknown | N/A | 184 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04518774 | Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial | unknown | Early Phase 1 | 8 | Beijing 302 HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04167007 | FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX(GEMFOX) | unknown | Phase 3 | 400 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT04513119 | The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis. | unknown | — | 100 | Southwest Hospital, ChinaOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04297202 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma(HCC-009) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT04503967 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer(OASIS) | unknown | Phase 2 | 48 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2020 | clinicaltrials |
| NCT04494022 | Role of CEUS as a Secondary Diagnostic Modality | unknown | N/A | 120 | Seoul National University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03642561 | Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE | unknown | Phase 2 / Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02169765 | HR Versus RFA for Early Stage HCC(ARTC-HCC) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 27, 2021source: clinicaltrials